Represented Crown Laboratories in litigation alleging false advertising of Crown Laboratories' Blue Lizard Australian Sunscreen products. Dismissed.
Representing Crown Laboratories in a consolidated, putative class action relating to the manufacturing, distribution, marketing and sale of an OTC benzoyl peroxide acne treatment and its alleged contamination with benzene. Preliminary settlement achieved.
Representing Teva Pharmaceuticals in putative class action litigation alleging an anti-competitive reverse payment arising out of a patent litigation settlement concerning the epilepsy drug Lamictal® (lamotrigine).
Representing Teva Pharmaceuticals and Natco Pharma in a putative class action litigation alleging an anti-competitive reverse payment arising out of a patent litigation settlement concerning the drug Revlimid® (lenalidomide).
Represented Teva Pharmaceuticals in litigation alleging breach of an asset purchase agreement relating to the drug Amrix®.
Represented Ranbaxy in multidistrict putative class action litigation arising out of a patent litigation settlement concerning the cholesterol drug Lipitor®. Kirkland secured a complete victory for its clients. Affirmed on appeal.
Represented CorrectCare Integrated Health, a third-party administrator for corrections facilities, in putative class action arising out of a data breach targeting its network.
Represented the Association for Accessible Medicines (AAM) in litigation challenging the constitutionality of a California law banning reverse payment settlements (a/k/a pay-for-delay agreements). Successfully challenged the state drug law as unconstitutional under the dormant Commerce Clause.
Represented a Fortune 20 Company in an FTC order compliance investigation relating to online purchase term disclosures for subscription services and other online purchases. In 2023, the FTC notified the company that it was closing its inquiry without further action.
